Personal stories

These GI conditions sound similar, and they also share some symptoms. But IBS and IBD are distinct disorders—especially when it comes to treatment and the risk of complications.

Inflammatory bowel disease doesn’t have a cure—yet. But the recent FDA approval of a promising medication is the latest in a long line of treatments from Johnson & Johnson that are helping patients with IBD.

After decades of commitment to understanding this neurodegenerative disease, company scientists have developed innovative therapies and tools that can potentially slow its progression and ease the psychological toll on patients and caretakers. A cure is still elusive—but preventing the disease may be within reach.

Inflammation is the body’s natural response to injury or infection. But when it lingers, inflammation can lead to immune-mediated inflammatory diseases. Learn how Johnson & Johnson is innovating to help bring relief to those living with chronic inflammatory conditions.

Here’s an infographic breakdown of the company’s second-quarter earnings results, including key highlights from its Innovative Medicine and MedTech businesses.

Health workers and first responders bear a double burden as survivors themselves, dealing with their own losses while helping their communities recover and rebuild in the aftermath of a disaster.

As Johnson & Johnson continues to make progress toward meeting its climate goals, learn about some of the employees who are working to impact both human health and the health of the planet.

SwipeRx is equipping pharmacies in Southeast Asia to advance patient care and transform global health. J&J Impact Ventures, an investment fund within the J&J Foundation, provided SwipeRx tailored pro bono services from J&J employees, which has proven instrumental in shaping the company’s future.

Eleven high school students from New Jersey—each representing a different congressional district—traveled to Washington, D.C., earlier this year to participate in the Close Up Foundation’s Washington, D.C. civic engagement program as Johnson & Johnson Scholars.

A Johnson & Johnson scientist explains how the new Acuvue® Oasys Max 1-Day Multifocal for Astigmatism contact lens also filters blue light, supports the eye’s natural tear film and helps eyes easily switch focus from distance to reading.